Socio-economics of personalized medicine in Asia
"The second decade of the 21st century has witnessed a new surge in emphasis on personalized medicine based on analysis of an individual's unique genetic make-up as a means to enable more precise diagnosis, treatment and prevention of diseases. This book attempts to contribute to this grow...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | Inglés |
| Published: |
New York :
Routledge
2016.
2017. |
| Series: | Routledge studies in the sociology of health and illness.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009433686206719 |
Table of Contents:
- Cover; Title; Copyright; Dedication; Contents; Acknowledgments; 1 Introduction; Personalized medicine and population-based research and development; What is a population? Race and genetics in North America; Personalized medicine, pharmacogenomics, and pharmacoethnicity; Why Asia?; Time, space, and the emergent other; Genomics in Asia and the unfolding dynamics of othering; Current research infrastructure and development concerning personalized medicine in Asia; Existing social-science studies of science and medicine performed in Asia; The illuminating question could be, when are you from?
- What is at stake when populations are ethnically or racially labeled?Chapter outline; 2 Regionalism and the study of human genetic variation in a transnational context: Asianism, nationalism, and the racialization of ethnicity; Introduction; The fundamental question of, when are you from?; Once upon a time: the unfolding character of the "Japanese" category; Effects of Japanese colonialism and regional integration on the notion of "Japanese"; Resisting being "othered": scientists in Asia define "Asian" genome diversity
- Ethnicity as a proxy for genetic diversity and the molecularization of ethnicities in AsiaConclusion; 3 Capitalizing on being "othered": precision medicine and race in the context of a globalized pharmaceutical industry; Introduction; Saving IRESSA; The larger significance of the story of IRESSA; Racializing clinical trials as a routine phenomenon; Local transformations; Pharmacogenomics, race, and post-marketing clinical trials; Conclusion; 4 Managing otherness: genomics and public health policy in Singapore; Introduction; Population aggregate data, ethnicity, and post-market drug vigilance
- Irinotecan and UGT1A1 genotypingCarbamazepine and HLA-B*1502 genotyping; Analysis of the prevailing practices noted above; The historical emergence of "Malay" as a group during the precolonial era; "Malayness" during the colonial era; "Malayness" in the Malay Peninsula in the postcolonial era; The case of the Malay in Singapore; Conclusion; 5 Cancer genomics in clinics; Introduction; Using ethnicity or race as a basis of clinical decision-making; Personalized medicine in clinical practice: drug efficacy; Personalized medicine in clinical practice: drug toxicities
- Personalized medicine in clinical practice: preventive medicineConclusion; 6 Socio-economic factors and ethical dilemmas in personalized medicine provision; Introduction; Genome-based personalized medicine is effective but not curative; moreover, it can be prohibitively expensive; Should the cost of a cancer drug be part of the treatment decisions?; Who should be expected to interpret genetic tests when cancer is a "context-dependent manifestation"?; Privacy concerns and the potential for genetic discrimination at the level of the individual and the group
- Should genome-based pharmaceuticals be the primary approach to treating cancer?
